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1 The rat homologue of the P2Y1 receptor has been heterologously expressed in 1321N1 human
astrocytoma cells and in C6 rat glioma cells.
2 As has been shown previously for the turkey and human P2Y1 receptors, the rat P2Y1 receptor
expressed in either cell type responded to 2MeSATP with increases in inositol phosphate accumulation
that were competitively blocked by the antagonist PPADS. Neither of the wild type cell lines exhibited
inositol phosphate responses to P2Y1 receptor agonists.
3 Expression of the rat P2Y1 receptor did not confer a capacity of 2MeSATP to inhibit adenylyl cyclase
activity in 1321N1 cells. Moreover, the inhibition of adenylyl cyclase mediated by an endogenous P2Y
receptor of C6 glioma cells was not enhanced by expression of the rat P2Y1 receptor. The P2Y receptor-
mediated inhibition of adenylyl cyclase in C6 glioma cells expressing both the endogenous P2Y receptor
and the rat P2Y1 receptor remained unaected by PPADS.
4 Since the P2Y receptor responsible for inhibition of adenylyl cyclase in C6 glioma cells does not share
the pharmacological or functional properties of the P2Y1 receptor, even when both receptors originate
from the same species and are simultaneously expressed in the same cell line, it is concluded that the
P2Y1 receptor is distinct from an endogenous P2Y receptor in C6 cells that couples to inhibition of
adenylyl cyclase.
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Introduction
The family of G protein-coupled P2Y receptors mediates a
broad array of physiological responses to extracellular nu-
cleotides (Dubyak & El-Moatassim, 1993). Mammalian re-
ceptors have been identi®ed that respond to either adenine
(P2Y1) or uridine nucleotides (P2Y4, P2Y6), or to both (P2Y2)
(Fredholm et al., 1997). All of the cloned P2Y receptors have
been shown to activate phospholipase C and mobilize calcium
when expressed in 1321N1 human astrocytoma cells (Filtz et
al., 1994; Parr et al., 1994; Communi et al., 1995; 1996; Chang
et al., 1995; Nguyen et al., 1995; Schachter et al., 1996).
At least two additional receptors for adenine nucleotides
have been proposed to exist but have not been cloned. A re-
ceptor (the P2T receptor) that mediates adenosine 5'-dipho-
sphate (ADP)-stimulated platelet aggregation has been
thought (Hourani & Hall, 1994) to dier from the adenine
nucleotide-sensitive P2Y1 receptor, since it inhibits adenylyl
cyclase and ATP and ATP analogues act as antagonists of the
P2T receptor, while functioning as agonists for mammalian
P2Y1 receptors (Filtz et al., 1994; Schachter et al., 1996).
However, Leon and coworkers have recently proposed that the
P2T and P2Y1 receptors are in fact the same signalling protein
(Leon et al., 1997). Another adenine nucleotide-sensitive re-
ceptor has been proposed to be endogenously expressed by C6
rat glioma cells (Pianet et al., 1989; Boyer et al., 1993), and a
receptor with similar properties has been shown to exist on rat
brain microvascular endothelial cells (Vigne et al., 1994;
Feolde et al., 1995). This receptor (which will be tentatively
referred to as the P2Y-C6 receptor) exhibits an agonist selec-
tivity that is similar, but not identical, to the P2Y1 receptor
(Boyer et al., 1993). However, these two receptors are more
clearly distinguished on the basis of their dierential functional
coupling and antagonist selectivities. The P2Y1 receptor se-
lectively stimulates inositol phosphate accumulation and ago-
nist activation of this response is competitively blocked
by pyridoxal-phosphate - 6 - azophenyl - 2',4' - disulphonic acid
(PPADS) (Boyer et al., 1994) and adenosine-3',5'-biphosphate
(Boyer et al., 1996). In contrast, the P2Y-C6 receptor couples
to the inhibition of adenylyl cyclase (Boyer et al., 1993; 1994;
1995) and is insensitive to these antagonists (Boyer et al., 1994;
1996).
Since functional assessments of the P2Y1 receptor have
been carried out in turkey erythrocytes and in 1321N1 human
astrocytoma cells, while the P2Y-C6 receptor has been stu-
died in C6 glioma cells and possibly in rat microvascular
endothelial cells, we have previously considered the possibi-
lity that these two receptors might be identical and that the
apparent selectivity in functional coupling of the P2Y1 re-
ceptor is in¯uenced by the cell line in which it is expressed.
Thus, the human P2Y1 receptor was expressed in rat C6
glioma cells where it conferred a PPADS-sensitive, adenine
nucleotide-stimulated inositol phosphate response without
alteration of the endogenous P2Y-receptor-mediated adenylyl
cyclase response (Schachter et al., 1996). We concluded from
this study that the P2Y1 receptor couples selectively to
phospholipase C and is distinct from the endogenous P2Y
receptor of C6 cells that couples to inhibition of adenylyl
cyclase. This conclusion recently was questioned due to the
fact that the heterologous P2Y1 receptor expressed in rat cells
was of human origin rather than rat (Webb et al., 1996).
Moreover, Webb et al. proposed that the P2Y receptor
coupling to the inhibition of adenylyl cyclase in C6 rat
glioma and in B10 rat microvascular endothelial cells is, in
fact, the rat homologue of the P2Y1 receptor and that the
selectivity of functional coupling of the rat P2Y1 receptor is
determined by the cell line in which the receptor is expressed.
They also suggested that sequence dierences between the rat
receptor and the human or turkey P2Y1 receptors may ex-
plain the lack of sensitivity of the rat receptor to PPADS.
To examine more directly the pharmacological and func-
tional selectivity of the rat P2Y1 receptor we have expressed
this receptor in both 1321N1 human astrocytoma cells, which
do not express endogenous P2Y receptors, and in C6 rat
glioma cells, which express an endogenous P2Y receptor that
couples to the inhibition of adenylyl cyclase but does not1Author for correspondence.
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couple to the activation of inositol phosphate accumulation.
The results indicate that the rat P2Y1 receptor is pharmaco-
logically and functionally identical to previously studied hu-
man and avian P2Y1 receptor orthologues, and that P2Y1
receptors, irrespective of species of origin, selectively couple to
activation of phospholipase C rather than interacting with Gi
to attenuate adenylyl cyclase activity.
Methods
Ampli®cation and expression of the rat P2Y1 receptor
The rat P2Y1 receptor was ampli®ed with Pfu polymerase from
1 mg of rat genomic DNA by use of primers (5'GAG AGA
ATT CCT GAG TTG GAA AGA AGA GGA-3' for the sense
strand and 5'-GAG ACT CGA GTG GAT CTC CTG CCT
TCA CAA-3' for the antisense strand) designed to introduce
5'-EcoR1 and 3'-Xho1 restriction sites. The ampli®ed product
was ligated into the retroviral expression vector pLXSN and
sequenced by dideoxynucleotide chain termination. Retrovirus
encoding the rat P2Y1 receptor was produced in PA317 cells as
described by Comstock et al (1997) and was used to infect
1321N1 and C6 cells. Infected cells were selected with G418 for
two weeks before the functional assays.
Inositol phosphate accumulation
Cells were plated in 24 well plates at 16105 cells per well and
cultured for three days in DMEM containing 5% foetal bovine
serum. Cells were labelled for 24 h with 0.4 mCi of [3H]-myo-
inositol (20 Ci mmol71, American Radiolabeled Chemicals) in
200 ml of inositol-free, serum free DMEM. Agonists were
dissolved in 250 mM HEPES, pH 7.3, and 50 ml of a ®ve fold
concentrated stock solution containing 50 mM LiCl was added
to each well. Incubations proceeded for 15 min at 378C and
were terminated by rapidly aspirating the medium and adding
750 ml of boiling water containing 10 mM EDTA, pH 8.0.
After 20 min, the cell lysate was removed from the culture
plates and applied to Dowex AG1-X8 columns for isolation of
inositol phosphates (Berridge et al., 1983).
Cyclic AMP accumulation
Accumulation of adenosine 3':5'-cyclic monophosphate (cyclic
AMP) was carried out under similar conditions to the inositol
phosphate assay with the following modi®cations. Before the
assay, cells were labelled for 2 to 3 h with 1 mCi [3H]-adenine
(20 Ci mmol71, American Radiolabeled Chemicals) in 200 ml
of DMEM. Assays for stimulation of cyclic AMP accumula-
tion were initiated by addition of 50 ml of 250 mM HEPES, pH
7.5, containing 1 mM isobutyl methyl xanthine (IBMX) and
®ve fold concentrated nucleotide agonist. Assays for inhibition
of cyclic AMP accumulation also included forskolin at 30 mM
®nal concentration. Incubations proceeded for 15 min at 378C
and were terminated by rapidly aspirating the medium and
adding 750 ml of 5% trichloroacetic acid. [3H]-cyclic AMP was
isolated by Dowex and alumina chromatography (Salomon et
al., 1974).
Materials
Pfu DNA polymerase was purchased from Stratagene (La
Jolla, CA). Reagents for cycle sequencing were purchased as a
kit from Perkin Elmer (Foster City, CA). Cell culture reagents
were from Gibco BRL (Grand Island, NY) and chromato-
graphy resins were from Biorad (Hercules, CA). 2-Methyl-
thioadenosine triphosphate (2MeSATP) and pyridoxal-
phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) were
obtained from Research Biochemicals Inc. (Natick, MA). We
are grateful to Dr John Olsen (Department of Medicine,
University of North Carolina) for his kind gifts of PA317 cells
and the pLXSN vector.
Results
Wild type or vector-transfected 1321N1 or C6 cells did not
exhibit an inositol phosphate response to 2MeSATP or other
adenine nucleotide analogues (data not shown). In contrast,
2MeSATP markedly elevated inositol phosphate levels in both
1321N1 and C6 cells expressing the rat P2Y1 receptor (Figures
1a and b). The potency of 2MeSATP at the rat P2Y1 receptor
(EC50 approximately 30 nM in either cell population) was si-
milar to the potency observed previously at the expressed hu-
man and turkey P2Y1 receptors. Inclusion of the antagonist
PPADS (30 mM) resulted in an approximately ten fold right-
ward shift of the concentration-eect curve for 2MeSATP for
stimulation of inositol phosphate accumulation in both cell
types. This concentration of PPADS did not alter the inositol
phosphate response to the muscarinic agonist carbachol in
1321N1 cells (data not shown), demonstrating that PPADS
does not act nonspeci®cally on the phospholipase C signalling
pathway.
Examination of adenylyl cyclase responses in wild type and
in rat P2Y1 receptor-expressing C6 cells did not reveal dier-
ences in the capacity of 2MeSATP to decrease forskolin-sti-
mulated cyclic AMP accumulation (Figure 2). In the presence
of maximally eective concentrations of 2MeSATP cyclic






























































Figure 1 Eects of PPADS on 2MeSATP-stimulated inositol
phosphate accumulation in cells expressing the rat P2Y1 receptor.
(a) Inositol phosphate responses to 2MeSATP in 1321N1-rP2Y1 cells
were assessed in the absence (control) and presence of PPADS as
described in Methods. Assays were initiated by simultaneous addition
of 2MeSATP, without or with 30 mM PPADS (®nal concentration),
and 10 mM LiCl. Data shown are the average (vertical lines show
s.e.mean) of three experiments performed in triplicate and normalized
to the maximal response from each experiment (7,000 ± 12,000 c.p.m.
above a basal value of 2,300 c.p.m.) (b) Same as in (a) but performed
with C6-rP2Y1 cells stimulated for 10 min (maximal responses were
30,000 ± 50,000 c.p.m. above a basal activity of 6,400 c.p.m.).
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although the magnitude of cyclic AMP accumulation stimu-
lated by forskolin alone was somewhat less in C6-rP2Y1 cells
than in wild type C6 cells. The reason for this apparent re-
duction in forskolin-stimulated cyclic AMP accumulation in
C6-rP2Y1 cells was not investigated. The addition of PPADS
at 30 mM did not aect either the stimulation of cyclic AMP
accumulation by 30 mM forskolin, or the inhibition of cyclic
AMP accumulation by 2MeSATP. These data are consistent
with our previous observations that PPADS is a competitive
antagonist of the phospholipase C-activating P2Y1 receptor,
but is not an antagonist at the endogenous P2Y receptor of C6
glioma cells that inhibits adenylyl cyclase. Furthermore, the
data indicate that expression of the rat P2Y1 receptor in the
rat C6 cell line does not alter the cyclic AMP response to
2MeSATP.
Cyclic AMP accumulation was also examined in human
1321N1 cells expressing the rat P2Y1 receptor. 2MeSATP
neither stimulated nor inhibited cyclic AMP accumulation in
these cells (Figure 3). However, when the Gi-coupled M2
muscarinic receptor was expressed in 1321N1 cells a robust
inhibition of adenylyl cyclase was observed in response to
carbachol (Figure 3). Thus, the rat P2Y1 receptor markedly
activates phospholipase C (Figure 1a) under conditions in
which no functional coupling of this receptor to adenylyl
cyclase can be observed.
Discussion
Examination of second messenger coupling properties of the
cloned turkey and human P2Y1 receptors demonstrated that
both of these species orthologues activate phospholipase C
(PLC), but do not inhibit adenylyl cyclase activity when het-
erologously expressed in 1321N1 human astrocytoma cells
(Filtz et al., 1994; Schachter et al., 1996). In contrast, a P2Y
receptor that is endogenously expressed on rat C6 glioma cells
and apparently on rat B10 microvascular endothelial cells in-
hibits adenylyl cyclase but does not activate phospholipase C
(Pianet et al., 1989; Boyer et al., 1993; Feolde et al., 1995;
Webb et al., 1996). Based on data obtained from radioligand
binding studies with [35S]-dATPaS and from RT-PCR of rat
cell extracts, Webb and coworkers (1996) concluded that the
P2Y receptor promoting inhibition of adenylyl cyclase in the
rat microvascular endothelial and glioma cell lines is the rat
homologue of the P2Y1 receptor, and that the second mes-
senger coupling speci®city and antagonist sensitivity of the
P2Y1 receptor depends on either the species of origin of the
receptor, or the cell type in which it is expressed.
The conclusions previously made by Webb et al. regarding
the P2Y1 receptor are open to interpretation. First, the use of
[35S]-dATPaS as a ligand to label speci®cally the P2Y1 receptor
has been questioned (Schachter & Harden, 1997). Second, the
use of RT-PCR to identify species of expressed receptors is
problematic. For example, Webb et al. (1996) did not rule out
that small amounts of residual genomic DNA were ampli®ed
from B10 cells by illustrating that ampli®cation of the rat P2Y1
receptor sequence was reverse-transcriptase dependent.
Moreover, even under conditions where receptor sequence is
unambiguously demonstrated to arise from reverse-transcribed
mRNA, ampli®cation of a sequence from RT-PCR does not
prove that this sequence is responsible for the functional re-
sponses to nucleotides observed in these cells. The signi®cance
of the ®nding that degenerate oligonucleotide sequences am-
pli®ed only the rat P2Y1 sequence in extracts from B10 en-
dothelial cells or C6 glioma cells is unclear, since a Gi-linked
P2Y receptor would be expected to have low sequence
homology with the PLC-coupled P2Y1 receptor. Direct evi-
dence to support the contention that the rat P2Y1 receptor can
couple to the inhibition of adenylyl cyclase would require that
the ampli®ed sequence be expressed in a cell line where this
functional response to adenine nucleotides was then observed
as a consequence of receptor expression. Our results suggest
that this does not occur. That is, expression of the rat P2Y1
receptor in either 1321N1 or C6 glioma cells resulted in con-
ference of 2MeSATP-promoted inositol phosphate accumula-
tion that was antagonized by PPADS. However, expression of
the rat P2Y1 receptor neither conferred a capacity of 2Me-
SATP to modulate adenylyl cyclase activity in 1321N1 cells,







































Figure 2 Lack of eect of rP2Y1 receptor expression or PPADS on
2MeSATP-stimulated inhibition of cyclic AMP accumulation in rat
C6 glioma cells. Cyclic AMP accumulation was assessed in wild type
and in rP2Y1 receptor expressing C6 cells with 30 mM forskolin and
200 mM IBMX. Simultaneous addition of 2MeSATP reduced the
stimulation of cyclic AMP accumulation in the absence (open
symbols) or presence (solid symbols) of 30 mM PPADS. Data are
expressed as % conversion of incorporated label (360,000+
12,000 c.p.m. for wild type 180,000+20,000 for rP2Y1 expressing




























































Figure 3 Lack of eect of 2MeSATP on cyclic AMP accumulation
in 1321N1-rP2Y1 cells. The same cell line used for the data shown in
Figure 1a was examined for cyclic AMP accumulation in the absence
(control) or presence of 30 mM forskolin. Various concentrations of
2MeSATP were added simultaneously with forskolin and IBMX.
Data in the inset are from 1321N1 cells in which the M2-muscarinic
receptor has been expressed. Cyclic AMP accumulation was
stimulated by 30 mM forskolin in the absence (control) or presence
of 1 mM carbachol (CCh).
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cyclase activity in C6 cells. The inhibition of adenylyl cyclase
in C6 cells expressing the rat P2Y1 receptor was unaected by
PPADS. Thus, these data demonstrate that the rat P2Y1 re-
ceptor, like its human and avian homologues, couples selec-
tively to phospholipase C regardless of the cell line in which it
is expressed.
The conclusions by Webb et al. (1996), that the receptor
coupled to the inhibition of adenylyl cyclase was identical to
the rat P2Y1 receptor and that the functional coupling of this
receptor is determined by the cell type in which it is expressed,
have prompted Leon et al. (1997) to speculate that the platelet
P2T receptor is also identical to the P2Y1 receptor. While it is
quite possible that platelets express the P2Y1 receptor and that
this receptor may contribute to the physiological responses of
platelets to ADP, it is clear that the functional coupling re-
sponse in platelets ascribed to the P2T receptor (inhibition of
adenylyl cyclase) is distinct from that of the P2Y1 receptor.
Whether ATP, an antagonist at the P2T receptor, is a true
agonist at the P2Y1 receptor is a point of debate (see Leon et
al., 1997), but clearly establishing this dierence would further
distinguish these two receptors.
With the objective of developing compounds that selec-
tively target individual P2Y subtypes, it is important to
establish not only whether a given sequence is a functional
P2Y receptor but also whether a receptor in one tissue, cell
line or species is the same or dierent from the receptor
from another source. The cloned P2Y1 receptor and the yet
to be cloned endogenous P2Y receptor of C6 glioma cells
exhibit similar but not identical agonist selectivities, and
have been clearly distinguished through the use of the an-
tagonists PPADS and adenosine 3',5' bisphosphate (Boyer
et al., 1994; 1996; Schachter et al., 1996). Since the P2Y
receptor of C6 cells is both pharmacologically and func-
tionally distinguished from the rat P2Y1 receptor when
expressed in the same cell line, it is concluded that these
two entities are distinct receptor subtypes. However, this
conclusion does not rule out the possibility that when over-
expressed at very high levels the P2Y1 receptor might also
couple to Gi and adenylyl cyclase, as has been shown to be
the case for many Gq/PLC- and Gi/adenylyl cyclase-linked
receptors.
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